AEZS (MC $67 M) (Cash $45.7M ) FDA Decision on Nov 5= 300% Potential !

This Stock is one of the cheapest in the Biotech Sector . They have $45.7 M in Cash and a Market Cap of just $67 M thats ridiculous for a Company with such a Mega Pipeline .Another good sign is that Management bought 187k Shares in last few weeks .This is the Perfect time to load up before the speculators jumping in .

FDA decision on November 5 (Macrilen) and Interim Phase 3 results in 1H 2015 (ZoptEC) !

AEZS could run to $3-5 before FDA decision in early November .GL


Aeterna Zentaris (AEZS)

Market Cap: $67 M
Cash: $45.7 M
Price: $1.18

Shares Out: 56.5 M


Insider activity:
http://canadianinsider.com/node/7?menu_tickersearch=aez

Jun 10/14 Jun 10/14 Egbert, Carolyn Direct Ownership Common Shares 10 - Acquisition in the public market 100,000 $1.10 USD

Apr 14/14 Apr 11/14 Dodd, David Alan Direct Ownership Common Shares 10 - Acquisition in the public market 87,000 $1.15 USD


Pipeline
http://www.aezsinc.com/en/page.php?p=20


New Presentation
http://www.aezsinc.com/pdfdyn/AEZS presentation June 2014.pdf



MACRILEN?(macimorelin)

?Filing of a New Drug Application ("NDA") seeking approval for the commercialization of MACRILEN? as the firstavailable oral product indicated for the evaluation of Adult Growth Hormone Deficiency


. NDA currently undersubstantive review by the US Food and Drug
Administration with a Prescription Drug User Fee Act date of November 5,2014


Zoptarelin doxorubicin

Operate trial in support of achieving first interim analysis for
ZoptEC Phase 3 trial in H1-2015

Still a great entry point at this ridiculous low price ...

Buy rating and a 12-month price target of $3.00 per share

In a report released Thursday, H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage on AEterna Zentaris (NASDAQ: AEZS) with a Buy rating and a 12-month price target of $3.00 per share.

Analysts at H.C. Wainwright favor AEterna for the likelihood of its drug Macrilen passing its FDA review. Macrilen is an Adult Growth Hormone Deficiency (AGHD) detection treatment, expected to be approved by the PDUFA date of November 25 and acquired in-licenses approved the treatment expected by the end of 2014.

The Wainwright note also focused on Zoptarelin doxorubicin, with most sourced guidance anticipating its release in 2018. Zoptarelin is a high-purpose endometrial cancer treatment, with expected high growth into AEterna's share price over time.